Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed adenocarcinoma of the esophagus (\> 20 cm below the incisors) or gastroesophageal (GE) junction, untreated with chemotherapy, radiation therapy, and surgery. Endoscopy with biopsy and dilation was permitted.~* Tumor stage T2N0M0, T3N0M0, T1-3N+M0, or T1-3N0-1M1A as determined by imaging studies performed no greater than 4 weeks prior to registration, and biopsy, where appropriate. Celiac nodal metastasis (M1A disease) was permitted if other eligibility criteria were met. Data from endoscopic ultrasound and endoscopy were required for staging. The following imaging was required: CT scan with IV contrast and PET or PET+CT. If the PET/CT incorporates CT with IV contrast, then a separate CT is not required. If laparoscopy or other relevant procedures were performed, the data were to be incorporated into stage assignment. Any lesion suspicious for metastasis had to have been biopsied to prove eligibility.~* Tumor extension into cardia, if present, must have been no more than 2 cm.~* Tumors must have been considered surgically resectable (T1-3, not T4).~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Granulocytes \> 1,000/ mm³~* Platelets \> 100,000 μL~* Creatinine normal or creatinine clearance \> 60 mL/min~* Total serum bilirubin \< 1.5 mg/dL~* Fertile patients must use effective contraception~* History of a curatively treated malignancy from which the patient has been disease-free for ≥ 2 years and has a survival prognosis of \> 5 years~Exclusion Criteria:~* Pregnant or breast-feeding.~* Prior severe infusion reaction to a monoclonal antibody~* prior therapy specifically and directly targeting the epidermal growth factor receptor (EGFR) pathway~* Hypertension~* Uncontrolled diabetes~* Intercurrent illness that would likely interfere with protocol therapy or prevent surgical resection~* Any of the following within the past 6 months:~  * New York Heart Association class III-IV congestive heart failure~ * Cerebrovascular accident or transient ischemic attack~ * Unstable angina or myocardial infarction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant therapy, Surgery, adjuvant therapy (Type: EXPERIMENTAL): Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues